Sort   by:  
 Page size 
UnknownRandomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer.
Not available
S-EPMC5320944 | biostudies-literature
UnknownManagement of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
Not available
S-EPMC6481621 | biostudies-literature
UnknownT-cell defects in patients with ARPC1B germline mutations account for combined immunodeficiency.
Not available
S-EPMC6265646 | biostudies-literature
UnknownTherapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
Not available
S-EPMC8362594 | biostudies-literature
UnknownInterleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.
Not available
S-EPMC7953461 | biostudies-literature
UnknownA second update on mapping the human genetic architecture of COVID-19.
Not available
S-EPMC10482689 | biostudies-literature
UnknownX-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19.
Not available
S-EPMC8532080 | biostudies-literature
UnknownTherapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.
Not available
S-EPMC8362592 | biostudies-literature
UnknownThe global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023.
Not available
S-EPMC12687902 | biostudies-literature
UnknownGlobal burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
Not available
S-EPMC12535838 | biostudies-literature
Sort   by:  
 Page size